Document is current
Any future updates will be listed below
-
Authors
Hop, Paul J. https://orcid.org/0000-0002-9007-7436
Lai, Dongbing https://orcid.org/0000-0001-7803-580X
Keagle, Pamela J.
Baron, Desiree M.
Kenna, Brendan J.
Kooyman, Maarten https://orcid.org/0000-0002-9023-5617
Shankaracharya,
Halter, Cheryl
Straniero, Letizia
Asselta, Rosanna https://orcid.org/0000-0001-5351-0619
Bonvegna, Salvatore
Soto-Beasley, Alexandra I.
,
Wszolek, Zbigniew K. https://orcid.org/0000-0001-5487-1053
Uitti, Ryan J.
Isaias, Ioannis Ugo
Pezzoli, Gianni
Ticozzi, Nicola https://orcid.org/0000-0001-5963-7426
Ross, Owen A. https://orcid.org/0000-0003-4813-756X
Veldink, Jan H. https://orcid.org/0000-0001-5572-9657
Foroud, Tatiana M. https://orcid.org/0000-0002-5549-2212
Kenna, Kevin P. https://orcid.org/0009-0001-2712-7218
Landers, John E. https://orcid.org/0000-0001-8084-5043
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 6 May 2024
First Online: 10 June 2024
Competing interests
: Z.K.W. serves as principal investigator (PI) or co-PI on Biohaven Pharmaceuticals, Inc. (BHV4157-206) and Vigil Neuroscience, Inc. (VGL101-01.002, VGL101-01.201, positron emission tomography tracer development protocol, Csf1r biomarker and repository project, and ultrahigh field magnetic resonance imaging in the diagnosis and management of CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia) projects/grants. He serves as co-PI of the Mayo Clinic APDA Center for Advanced Research and as an external advisory board member for the Vigil Neuroscience, Inc., and as a consultant on neurodegenerative medical research for Eli Lilli and Company. J.H.V. reports to have sponsored research agreements with Biogen and Astra Zeneca. J.E.L. is a consultant for Illios Therapeutics, WCG Clinical and Biogen. The other authors declare no competing interests.
